Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Norway is in the process of establishing the Young Academy of Norway (Norwegian: Akademiet for yngre forskere). The first call for members was issued earlier this year and the nearly 160 young researchers applied and 20 of them are now becoming the founding members of the Young Academy of Norway.
Three OUS researchers have been accepted as members: Gro Elisabeth Lind, head of the Epigentics group at the Department of Molecular Oncology at the Institute for Cancer Research, Kyrre Eeg Emplem, principal investigator in Atle Bjørnerud's Functional MR Neuroimaging group at the Intervention Centre and Monica Aas from Ingrid Melle's group at the Division of Mental Health & Addiction.
Guro E. Lind is appointed the first leader of the Academy.
Harald A. Stenmark, leader of the "Cellular membrane dynamics group" at the Department of Molecular Cell Biology, OUS, and from Centre for Cancer Biomedicine at UIO has won this year's "Møbius award" - the annual prize for excellent research from the Research Council of Norway. The award amounts to 1 mill. NOK and is distributed Wednesday September 23rd in Oslo Konserthus.
(news article now updated with more links)
Dr. Anita Sveen and co-workers recently published a review article about alternative splicing in cancer in the journal Oncogene (journal impact factor 8.56). In this article, an overview of known aberrant splicing events in cancer-critical genes and their potential as cancer biomarkers is given. The article also discusses cancer-associated patterns of splicing on a genome-wide scale. Furthermore, the genes encoding splicing factors are found to be enriched for cancer-critical somatic mutations and to have dysregulated expression patterns. Several novel cancer-critical splicing factors are proposed.
Anders Jahre's Awards for Medical Research honor research of outstanding quality in basic and clinical medicine. The prizes are awarded by the University of Oslo and are among the largest within Nordic biomedical research. The prize is awarded by the University of Oslo after nomination by a committee appointed by the University. The award includes a grant of NOK 1,000,000.
The Anders Jahre Senior Medical Prize (the main prize) for 2015 is shared between Ludvig M. Sollid (UiO and OUS) and Rikard Holmdahl (KI, Stockholm).
Sollid is awarded for his groundbreaking research on coeliac disease.
Professor Erik Fosse from The Intervention Centre at the Division of Diagnostics and Intervention, OUS, has been awarded the University of Oslo Innovation prize for his creations within the fields of medicine and health service. He received the prize at a seremony taking place during the annual party for the University of Oslo September 2nd.
Erik Fosse is extensively presented in a feature article in the web newspaper of University of Oslo - Uniforum.
Two studies of PARP inhibition in malignant lymphocytes reveal differential phenotypical responses, DNA damage induction and repair during the cell cycle
In two studies that have been carried out in the Group for Molecular Radiation Biology at Section of Radiation Biology, the effects of PARP inhibitor Olaparib in malignant lymphocytes with or without functional ATM were studied in detail. Dose- and time-dependent effects of Olaparib on proliferation, cell cycle, DNA damage and cell death mechanism were analysed simultaneously on a single cell level.
The 2 articles have recently been been published in Cell Cycle.
Kaisa Haglund from Harald Stenmark's group at the Institute for Cancer Research, Oslo University Hospital, and Centre for Cancer Biomedicine, University of Oslo is awarded the Anders Jahre's prize for young medical researchers for the year 2015 in recognition of her outstanding scientific work on cellular mechanisms regulating cell division and cancer development. Haglund shares the prize with Professor Pernilla Lagergren from Karolinska Institutet. The prize sum is NOK 400,000.
Early 2000, Jónas Einarsson, CEO at the Radium Hospital Research Foundation, and Kaare Norum, former principal of the University of Oslo, realized that a natural cluster for cancer research, development and innovation emerged in the Oslo-area. Together they established Oslo Cancer Cluster, a research and industry cluster within cancer.
Oslo Cancer Cluster Innovation Park AS was officially opened August 24th 2015 by the Prime Minister of Norway, Erna Solberg.
An new English version of "The Research Handbook- from idea to publication" is available on Oslo University Hospital website as of August 27 2015.
The website presents both a Norwegian and English updated version of the Handbook, including simple "Downhill Ski Tracks" for Researchers, PhD students and their projects.
The Research Handbook is designed to provide guidance to hospital personnel,health researchers and biomedical researchers who would like to convert an idea into a high quality research project.
Norway's largest newspaper Aftenposten recently printed a chronicle on personalized cancer medicine, entitled "Should every cancer patient become their own research project"? Here, leader of the National Cancer Genomics Consortium, professor Ola Myklebost, and colleagues professors Per Eystein Lønning, Bjørn Tore Gjertsen and Ragnhild A. Lothe point out that in "personalized medicine", cancer patients remain the largest and increasing group that may benefit most from new treatment strategies.
The authors emphasize the importance of increase in national clinical trials and participation in high quality international studies for the benefit of the Norwegian cancer patient and to strengthen the Norwegian professional development and research.
Elen K. Møller – Dept. of Cancer Genetics
Oct 6, 2015
Sep 30, 2015
Sep 29, 2015
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
New medical therapies for heart failure
Nat Rev Cardiol (in press)
More selected publications